Skip to main content
Top
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma

Authors: Xiangshan Yang, Wenyuan Lv, Ranran Shi, Shaomei Cheng, Jing Zhang, Zhongfa Xu

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Papillary thyroid microcarcinoma (PMC) is the most common subtype of thyroid carcinomas with satisfactory prognosis. Crk-like (CrkL) adaptor protein was identified in the development of many carcinomas. However, the clinical implications of CrkL protein in PMC were still unknown. Here, we conducted immunohistochemistry to test and analyze CrkL expression in papillary thyroid carcinoma (PTC) (50 cases), PMC (50 cases), and nodular goiter (50 cases), and then western blot further identified the expression of CrkL proteins. In our present study, the positive rate and the mean optical density (MOD) value of CrkL expression in PTC and PMC tissues were statistically significantly different, compared with nodular goiter (p = 0.021, 0.037) and normal thyroid tissues (p = 0.003, 0.009), respectively. In addition, CrkL expression was not associated with age, gender, and tumor number. Conversely, significant differences between CrkL expression and metastasis (p < 0.01) and violation of capsule (p < 0.01) were observed. Notably, western blot indeed identified that the metastasis group of either PTC or PMC tissues had about twofold increased expression of CrkL compared with their non-metastasis groups (p < 0.05). In conclusion, CrkL is highly expressed in papillary thyroid carcinoma and papillary thyroid microcarcinoma and closely correlated to metastasis. Therefore, it is essential to carry out neck lymph node clearance in patients with papillary thyroid microcarcinoma.
Literature
1.
go back to reference Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRef Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.CrossRef
2.
go back to reference Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg. 1996;83:1674–83.CrossRef Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg. 1996;83:1674–83.CrossRef
3.
go back to reference Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, et al. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol. 2014;50:577–86.CrossRef Salama JK, Golden DW, Yom SS, Garg MK, Lawson J, McDonald MW, et al. ACR Appropriateness Criteria® thyroid carcinoma. Oral Oncol. 2014;50:577–86.CrossRef
4.
go back to reference Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63:908–11.CrossRef Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989;63:908–11.CrossRef
5.
go back to reference Walts AE, Pao A, Sacks W, Bose S. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. Hum Pathol. 2014;45:935–41.CrossRef Walts AE, Pao A, Sacks W, Bose S. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis. Hum Pathol. 2014;45:935–41.CrossRef
6.
go back to reference Vayisoglu Y, Ozcan C. Involvement of level IIb lymph node metastasis and dissection in thyroid cancer. Gland Surg. 2013;2:180–5.PubMedPubMedCentral Vayisoglu Y, Ozcan C. Involvement of level IIb lymph node metastasis and dissection in thyroid cancer. Gland Surg. 2013;2:180–5.PubMedPubMedCentral
7.
go back to reference Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, et al. Sunitinib therapy in metastatic papillary thyroid cancer. Tumori. 2013;99:285e–7.CrossRef Gori S, Foglietta J, Rossi M, Hamzaj A, Stocchi L, Galuppo C, et al. Sunitinib therapy in metastatic papillary thyroid cancer. Tumori. 2013;99:285e–7.CrossRef
8.
go back to reference Küçük NO, Tari P, Tokmak E, Aras G. Treatment for microcarcinoma of the thyroid—clinical experience. Clin Nucl Med. 2007;32:279–81.CrossRef Küçük NO, Tari P, Tokmak E, Aras G. Treatment for microcarcinoma of the thyroid—clinical experience. Clin Nucl Med. 2007;32:279–81.CrossRef
9.
go back to reference Li LC, Liu GD, Zhang XJ, Li YB. Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer. Cancer Chemother Pharmacol. 2014;73:439–49.CrossRef Li LC, Liu GD, Zhang XJ, Li YB. Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer. Cancer Chemother Pharmacol. 2014;73:439–49.CrossRef
10.
go back to reference Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini E. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol. 2013;38:269–79.PubMed Pedrazzini L, Baroli A, Marzoli L, Guglielmi R, Papini E. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up. Minerva Endocrinol. 2013;38:269–79.PubMed
11.
go back to reference Wybenga-Groot LE, McGlade CJ. Crystal structure of Src-like adaptor protein 2 reveals close association of SH3 and SH2 domains through β-sheet formation. Cell Signal. 2013;25:2702–8.CrossRef Wybenga-Groot LE, McGlade CJ. Crystal structure of Src-like adaptor protein 2 reveals close association of SH3 and SH2 domains through β-sheet formation. Cell Signal. 2013;25:2702–8.CrossRef
12.
go back to reference Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32:5429–38.CrossRef Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, et al. Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth. Oncogene. 2013;32:5429–38.CrossRef
13.
go back to reference Yao C, Lv S, Han M, Zhang J, Zhang Y, Zhang L, et al. The association of Crk-like adapter protein with poor prognosis in glioma patients. Tumour Biol. 2014;35:5695–700.CrossRef Yao C, Lv S, Han M, Zhang J, Zhang Y, Zhang L, et al. The association of Crk-like adapter protein with poor prognosis in glioma patients. Tumour Biol. 2014;35:5695–700.CrossRef
14.
go back to reference Yanagi H, Wang L, Nishihara H, Kimura T, Tanino M, Yanagi T, et al. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion. Biochem Biophys Res Commun. 2012;418:104–9.CrossRef Yanagi H, Wang L, Nishihara H, Kimura T, Tanino M, Yanagi T, et al. CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion. Biochem Biophys Res Commun. 2012;418:104–9.CrossRef
15.
go back to reference Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7:13.CrossRef Birge RB, Kalodimos C, Inagaki F, Tanaka S. Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun Signal. 2009;7:13.CrossRef
16.
go back to reference Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2013;52:890–9.CrossRef Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2013;52:890–9.CrossRef
17.
go back to reference Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X, et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 2013;34:2891–7.CrossRef Zhao T, Miao Z, Wang Z, Xu Y, Wu J, Liu X, et al. Overexpression of CRKL correlates with malignant cell proliferation in breast cancer. Tumour Biol. 2013;34:2891–7.CrossRef
18.
go back to reference Wang J, Che YL, Li G, Liu B, Shen TM, Wang H, et al. Crk and CrkL present with different expression and significance in epithelial ovarian carcinoma. Mol Carcinog. 2011;50:506–15.CrossRef Wang J, Che YL, Li G, Liu B, Shen TM, Wang H, et al. Crk and CrkL present with different expression and significance in epithelial ovarian carcinoma. Mol Carcinog. 2011;50:506–15.CrossRef
19.
go back to reference Bell ES, Park M. Models of crk adaptor proteins in cancer. Genes Cancer. 2012;3:341–52.CrossRef Bell ES, Park M. Models of crk adaptor proteins in cancer. Genes Cancer. 2012;3:341–52.CrossRef
20.
go back to reference Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, et al. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res. 2009;7:1582–92.CrossRef Watanabe T, Tsuda M, Tanaka S, Ohba Y, Kawaguchi H, Majima T, et al. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res. 2009;7:1582–92.CrossRef
21.
go back to reference Zheng J, Machida K, Antoku S, Ng KY, Claffey KP, Mayer BJ. Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation. Oncogene. 2010;29:6378–89.CrossRef Zheng J, Machida K, Antoku S, Ng KY, Claffey KP, Mayer BJ. Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation. Oncogene. 2010;29:6378–89.CrossRef
22.
go back to reference Janoštiak R, Tolde O, Brůhová Z, Novotný M, Hanks SK, Rösel D, et al. Tyrosine phosphorylation within the SH3 domain regulates CAS subcellular localization, cell migration, and invasiveness. Mol Biol Cell. 2011;22:4256–67.CrossRef Janoštiak R, Tolde O, Brůhová Z, Novotný M, Hanks SK, Rösel D, et al. Tyrosine phosphorylation within the SH3 domain regulates CAS subcellular localization, cell migration, and invasiveness. Mol Biol Cell. 2011;22:4256–67.CrossRef
23.
go back to reference Wang H, Linghu H, Wang J, Che YL, Xiang TX, Tang WX, et al. The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3. Tumour Biol. 2010;31:59–67.CrossRef Wang H, Linghu H, Wang J, Che YL, Xiang TX, Tang WX, et al. The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3. Tumour Biol. 2010;31:59–67.CrossRef
24.
go back to reference Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1:608–25.CrossRef Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 2011;1:608–25.CrossRef
25.
go back to reference Natsume H, Shinmura K, Tao H, Igarashi H, Suzuki M, Nagura K, et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med. 2012;10:97.CrossRef Natsume H, Shinmura K, Tao H, Igarashi H, Suzuki M, Nagura K, et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J Transl Med. 2012;10:97.CrossRef
26.
go back to reference Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119:1135–9.CrossRef Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119:1135–9.CrossRef
Metadata
Title
The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma
Authors
Xiangshan Yang
Wenyuan Lv
Ranran Shi
Shaomei Cheng
Jing Zhang
Zhongfa Xu
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2561-1

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine